Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Files

Cancer Reports - 2025 - Garcia Fasanella - Evaluation of Clinical Outcomes and Treatment Complications in Hairy Cell.pdf (641.86 KB)

Document type

Article

Version

Published version

Publication date

2025-10-01

Publication license

cc-by (c) Fasanella, M.Garcia et al., 2025
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/223778

Evaluation of Clinical Outcomes and Treatment Complications in Hairy Cell Leukemia: A Single‐Center Retrospective Analysis

Journal Title

Authors

Director/Tutor

Journal ISSN

Volume Title

Related resource

https://doi.org/10.1002/cnr2.70356

Abstract

Background Hairy cell leukemia (HCL) is a rare disorder characterized by splenomegaly, pancytopenia, and proliferation with hairy lymphocytes. Treatment is based on purine analogs and anti-CD20 antibodies, often resulting in significant adverse effects. Aims The objective of this study is to describe the frequency, clinical, and biological characteristics of a historic cohort of HCL patients in our center and the most common side effects related to treatment with purine analogs. Methods and Results This study analyzed 21 patients treated between 2009 and 2023, focusing on clinical characteristics, treatment response, complications, and survival outcomes. Cladribine treatment achieved complete response in 77.8% of patients. The 5-year OS and PFS were 100% and 91.7%, respectively. Infections, pathogens such as herpes viruses and mycobacteria, were major complications, impacting 38% of patients. Severe skin reactions were noted in patients treated with cladribine. Conclusion The study highlights cladribine's effectiveness in inducing remission in HCL patients, pointing out the significant risks of infections and other adverse effects. Introducing targeted treatments like BRAF inhibitors provides promising alternatives, especially for resistant patients or those intolerant to purine analogs. Future strategies should focus on integrating targeted therapies to reduce treatment-related morbidity.

Subject

Malalties inflamatòries intestinals, Immunosupressió, Estabilitat dels medicaments

Subject (English)

Inflammatory bowel diseases, Immunosuppression, Drug stability

Citation

Collections

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citation

FASANELLA, M.Garcia, et al. Evaluation of Clinical Outcomes and Treatment Complications in Hairy Cell Leukemia: A Single‐Center Retrospective Analysis. Cancer Reports. 2025. Vol. 8, num. 10, pags. e70356. ISSN 2573-8348. [consulted: 15 of August of 2026]. Available at: https://hdl.handle.net/2445/223778

Export metadata

JSON - METS

Share record